Why the study?
The 2022 ESC cardio-oncology guidelines provide comprehensive recommendations for individualized cardiac care in oncology patients, supplemented by expert practical comments to optimize implementation.
This document provides practical expert commentary to facilitate the clinical application of the 2022 ESC cardio-oncology guidelines.
Supports optimized CV risk management in cancer patients; extends 2022 ESC guidelines with practical Polish expert commentary for clinicians and researchers.
The 2022 European Society of Cardiology (ESC) guidelines [1] are a comprehensive document, prepared jointly by experts in cardiology and oncology. In the case of an oncological patient, it is necessary to individualize care in relation to the cardiological condition, the stage of the cancer and the type of potential anti-cancer therapy. Cardiac care optimisation should be undertaken before the start of oncological therapy, and continued during oncological therapy, as well as long-term after its completion [2]. The published ESC Guidelines were supplemented with a practical comments of a team of polish cardiology and oncology experts.
No takes yet. Share an insight, caveat, or question.
Leszek et al. (2023) conducted an editorial in Cancer and cardiovascular disease (Cardio-oncology). 2022 ESC cardio-oncology guidelines was evaluated. A multidisciplinary team of Polish experts provided practical commentary on the 2022 ESC cardio-oncology guidelines to optimize cardiovascular risk stratification and management in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: